You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR XEN1101


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for XEN1101

Trial ID Title Status Sponsor Phase Summary
NCT03340220 ↗ Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN1101 Unknown status Xenon Pharmaceuticals Inc. Phase 1 The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, tolerability and PK of both single ascending doses (SAD) and multiple ascending doses (MAD) of XEN1101 in healthy subjects. In addition to safety and PK data, the clinical trial has been designed to include a pharmacodynamic read-out by incorporating a pilot transcranial magnetic stimulation (TMS) sub-study. The TMS model sub-study is designed to demonstrate delivery of XEN1101 into the central nervous system and to observe a change in cortical excitability as measured by EEG and/or EMG activity. It is estimated there will be approximately 64 subjects in the planned SAD and MAD cohorts.
NCT03468725 ↗ Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 Completed Xenon Pharmaceuticals Inc. Phase 1 The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will eventuate the safety, tolerability, pharmacokinetics (PK) and effects on transcranial magnetic stimulation (TMS) of oral doses of XEN1101 in healthy male subjects.The TMS procedure is designed to demonstrate delivery of XEN1101 into the central nervous system and to observe a change in cortical excitability as measured by EEG and/or EMG activity. It is estimated there will be approximately 15 subjects in the planned study.
NCT03796962 ↗ A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Active, not recruiting NCGS, Inc. Phase 2 The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
NCT03796962 ↗ A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Active, not recruiting Xenon Pharmaceuticals Inc. Phase 2 The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
NCT04827901 ↗ XEN1101 for Major Depressive Disorder Recruiting Baylor College of Medicine Phase 2 This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
NCT04827901 ↗ XEN1101 for Major Depressive Disorder Recruiting National Institute of Mental Health (NIMH) Phase 2 This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for XEN1101

Condition Name

Condition Name
Intervention Trials
Focal Epilepsy 2
Focal Onset Seizures 2
Healthy Volunteers 2
Major Depressive Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Seizures 4
Depression 2
Epilepsy 2
Epilepsies, Partial 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for XEN1101

Trials by Country

Trials by Country
Location Trials
United States 30
United Kingdom 6
Spain 4
Canada 2
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
California 2
Texas 2
New York 2
Maryland 1
Maine 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for XEN1101

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 4
Phase 2 3
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 3
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XEN1101

Sponsor Name

Sponsor Name
Sponsor Trials
Xenon Pharmaceuticals Inc. 9
Worldwide Clinical Trials 4
NCGS, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 10
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.